Qiagen Future Growth

Future criteria checks 1/6

Qiagen is forecast to grow earnings and revenue by 11.3% and 6.1% per annum respectively. EPS is expected to grow by 11.5% per annum. Return on equity is forecast to be 12.1% in 3 years.

Key information

11.3%

Earnings growth rate

11.5%

EPS growth rate

Life Sciences earnings growth	15.8%
Revenue growth rate	6.1%
Future return on equity	12.1%
Analyst coverage	Good
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

May 26

Is Qiagen (NYSE:QGEN) A Risky Investment?

Apr 29

Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Mar 30

Earnings and Revenue Growth Forecasts

NYSE:QGEN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,297	497	484	767	15
12/31/2025	2,145	442	495	656	20
12/31/2024	2,010	398	447	583	20
12/31/2023	1,965	341	297	459	N/A
9/30/2023	1,956	485	302	468	N/A
6/30/2023	1,979	490	403	555	N/A
3/31/2023	2,000	505	457	616	N/A
12/31/2022	2,142	423	566	715	N/A
9/30/2022	2,226	488	660	826	N/A
6/30/2022	2,261	539	580	770	N/A
3/31/2022	2,313	563	556	755	N/A
12/31/2021	2,252	513	432	639	N/A
9/30/2021	2,240	311	516	745	N/A
6/30/2021	2,190	480	337	592	N/A
3/31/2021	2,065	449	239	571	N/A
12/31/2020	1,870	359	154	458	N/A
9/30/2020	1,713	191	10	298	N/A
6/30/2020	1,612	14	108	333	N/A
3/31/2020	1,550	-31	152	302	N/A
12/31/2019	1,526	-41	56	331	N/A
9/30/2019	1,516	-25	60	332	N/A
6/30/2019	1,511	196	58	342	N/A
3/31/2019	1,507	188	87	356	N/A
12/31/2018	1,502	190	209	359	N/A
9/30/2018	1,496	90	189	325	N/A
6/30/2018	1,482	78	189	324	N/A
3/31/2018	1,453	55	141	275	N/A
12/31/2017	1,418	40	162	287	N/A
9/30/2017	1,387	89	N/A	311	N/A
6/30/2017	1,362	75	N/A	323	N/A
3/31/2017	1,347	82	N/A	353	N/A
12/31/2016	1,338	80	N/A	342	N/A
9/30/2016	1,320	123	N/A	328	N/A
6/30/2016	1,296	123	N/A	331	N/A
3/31/2016	1,281	126	N/A	303	N/A
12/31/2015	1,281	130	N/A	317	N/A
9/30/2015	1,293	104	N/A	310	N/A
6/30/2015	1,315	105	N/A	303	N/A
3/31/2015	1,326	113	N/A	305	N/A
12/31/2014	1,345	116	N/A	288	N/A
9/30/2014	1,345	151	N/A	291	N/A
6/30/2014	1,331	157	N/A	284	N/A
3/31/2014	1,315	72	N/A	259	N/A
12/31/2013	1,302	69	N/A	259	N/A
9/30/2013	1,287	44	N/A	271	N/A
6/30/2013	1,270	32	N/A	263	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: QGEN's forecast earnings growth (11.3% per year) is above the savings rate (2.3%).

Earnings vs Market: QGEN's earnings (11.3% per year) are forecast to grow slower than the US market (14.4% per year).

High Growth Earnings: QGEN's earnings are forecast to grow, but not significantly.

Revenue vs Market: QGEN's revenue (6.1% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: QGEN's revenue (6.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (12.1%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Qiagen Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Recent updates

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Full year 2023 earnings: EPS misses analyst expectations

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Full year 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings: EPS misses analyst expectations

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

CFO, MD & Member of Management Board recently sold US$1.3m worth of stock

CFO, MD & Member of Management Board notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Now 20% undervalued

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings: EPS misses analyst expectations

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Board Member recently sold US$218k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Full year 2022 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Qiagen stock down after BHF downgrades rating to Neutral

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

QIAGEN Adds New Biopharma Products to QIAcuity Digital PCR Portfolio and Launches Expert Custom Assay Design Service